collaboration

Avapritinib is sold by Blueprint Medicines as Ayvakit for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation.

The companies will explore the IDE196 and Xalkori combination in solid tumors with GNAQ or GNA11 mutations, such as metastatic uveal melanoma.

The company hopes the collaboration will allow it to home in on a molecularly defined population of patients likely to benefit from its targeted agent LP-184.

Promega will develop its microsatellite instability assay as a companion diagnostic for Incyte's anti-PD-1 drug candidate retifanlimab in endometrial cancer.

The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.

The lab will use its GEM ExTra test to identify patients with NRG1 fusion-positive solid tumors who may be eligible to enroll in the Phase II CRESTONE trial.

The companies will jointly develop CAR T-cell therapies designed to inhibit HPK1 gene expression, which has been shown to lead to T-cell exhaustion. 

Covance hopes to improve and accelerate oncology clinical trial matching with the Tempus technology platform and network.

The company will work with university researchers to evaluate its predictive immune modeling technology in personalizing the use of immune checkpoint inhibitors.

Merck and Seattle Genetics will codevelop the antibody drug conjugate ladiratuzumab vedotin, while Merck gains ex-US commercialization rights to the HER2 inhibitor Tukysa.